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ABSTRACT Initial studies suggested that major histo-
compatibility complex class I-restricted viral epitopes could
be predicted by the presence of particular residues termed
anchors. However, recent studies showed that nonanchor
positions of the epitopes are also significant for class I binding
and recognition by cytotoxic T lymphocytes (CTLs). We
investigated if changing nonanchor amino acids could in-
crease class I affinity, complex stability, and T-cell recogni-
tion ofa natural viral epitope. This concept was tested by using
the HLA-A*0201-restricted human immunodeficiency virus
type 1 epitope from reverse transcriptase (pol). Position 1
(P1) amino acid substitutions were emphasized because P1
alterations may not alter the T-cell receptor interaction. The
peptide with the Pl substitution of tyrosine for isoleucine
(I1Y) showed a binding affinity for HLA-A*0201 similar to
that of the wild-type pol peptide in a cell lysate assembly assay.
Surprisingly, IlY significantly increased the HLA-A*0201-
peptide complex stability at the cell surface. I1Y sensitized
HLA-A*0201-expressing target cells for wild-type pol-specific
CTL lysis as well as wild-type pol. Peripheral blood lympho-
cytes from three HLA-A2 HIV-seropositive individuals were
stimulated in vitro with I1Y and wild-type pol. IIY stimulated
a higher wild-type pol-specific CTL response than wild-type
pol in all three donors. Thus, IlY may be an "improved"
epitope for use as a CTL-based human immunodeficiency
virus vaccine component. The design ofimproved epitopes has
important ramifications for prophylaxis and therapeutic vac-
cine development.
CD8+ cytotoxic T lymphocytes (CTLs) play a major role in the
clearance of viruses (1). The T-cell receptor (TCR) expressed
by the CTL recognizes a trimolecular complex consisting of a
major histocompatibility complex (MHC) class I heavy chain,
032-microglobulin, and a peptide of endogenous origin (2). The
peptide is usually 8-10 amino acids in length and interacts with
the class I molecule's binding pockets. Peptides restricted to a
specific class I molecule contain predominate amino acids,
termed anchors, at particular positions (2). However, presence
of favored residues at the anchor positions does not necessarily
confer high affinity (3-5).
Peptides which bind to the same MHC molecule have a
range of affinities (4, 5). Among high-affinity HLA-A*0201-
restricted peptides, particular amino acids were over-
represented at nonanchor positions (4). Our mutational anal-
yses of HLA-A*0201 demonstrated that mutations in any of
the MHC binding pockets can have a dramatic effect on both
peptide binding and CTL recognition (6-9). These data show
that a peptide's nonanchor positions contribute significantly to
its free energy of binding. Improvement of a known HLA-
A*0201 epitope's affinity may be possible by changing non-
anchor amino acids, thereby enhancing the interaction be-
tween the peptide and the heavy chain.
The ability to improve a natural epitope through nonanchor
substitutions was tested by using a human immunodeficiency
virus (HIV)-specific CTL response. The HLA-A*0201-
restricted HIV-1 polymerase (pol) epitope (10) was investi-
gated due to (i) its high sequence conservation among HIV-1
strains (95.1%) (ref. 11 and J.A.F., unpublished data), (ii) its
relatively low affinity for HLA-A*0201 (4, 5), and (iii) the
frequent observation of a CTL response to this epitope among
HIV-1-positive individuals (12). Improvement of this epitope
for immunotherapy is beneficial, since HLA-A2 is the most
common human class I allele worldwide (13).
We focused on position 1 (P1) amino acid alterations due to
its interaction with both MHC and TCR. Structural studies of
five peptides bound to HLA-A*0201 showed that the orien-
tation of the P1 side chains was very similar (14). The majority
of the P1 residue was buried within the class I cleft. Therefore,
alterations of the amino-terminal side chain may allow for
higher affinity between the peptide and the heavy chain
without altering TCR interaction. Our analysis of P1-
substituted peptides bound to HLA-B27 subtypes supports this
concept (15). Peptides with increased affinity may be able to
enhance stimulation of natural epitope-specific CTL. Such
"improved" peptides may be useful for CTL-based immuno-
therapy and prophylaxis.
MATERIALS AND METHODS
Cell Lines. T2 cells are defective in antigen presentation
(16). T2 cells were maintained in RPMI medium 1640 (Me-
diatech, Washington, DC) containing 5% calf serum (Hy-
Clone), and 2 mM L-glutamine (GIBCO). C1R-A2 and ClR-
neo cells are derivatives of the HLA-A null human B-lymphoid
cell line Hmy2.ClR (ClR), transfected with HLA-A*0201 and
pSV2-neo or pSV2-neo alone, respectively (9). The ClR
transfectants were maintained in the same media supple-
mented with G418 (GIBCO) at 400 ,ug/ml.
Peptides. Peptides were synthesized by the University of
North Carolina/Program in Molecular Biology and Biotech-
nology Micro Protein Chemistry Facility, using fluorenylme-
thoxycarbonyl (Fmoc) chemistry. The HLA-A*0201-restricted
HIV-1 pol epitope corresponds to amino acid residues 476-
484 of the HIV-1 reverse transcriptase (ILKEPVHGV) (10).
The HLA-A*0201-restricted HIV-1 p17 gag epitope (amino
acid residues 77-85: SLYNTVATL) is used as a control (17).
Sequences of the substituted peptides are shown in Table 1.
The peptides were purified by HPLC, and peptide concentra-
tion was determined by amino acid analysis at the Protein
Chemistry Laboratory at the University of North Carolina at
Abbreviations: MHC, major histocompatibility complex; CTL, cyto-
toxic T lymphocyte; HIV, human immunodeficiency virus; TCR,
T-cell receptor; P1, position 1; PBL, peripheral blood lymphocyte;
WT, wild type; W, vaccinia virus; EBV, Epstein-Barr virus.
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Table 1. pol substitution peptide sequences
Abbrev. P1 P2 P3 P4 P5 P6 P7 P8 P9
WT I L K E P V H G V
I1A A L K E P V H G V
IlF F L K E P V H G V
I1G G L K E P V H G V
I1H H L K E P V H G V
IlK K L K E P V H G V
IlL L L K E P V H G V
i1M M L K E P V H G V
I1R R L K E P V H G V
Iiv V L K E P V H G V
I1W W L K E P V H G V
IlY Y L K E P V H G V
K3F I L F E P V H G V
K3Y I L Y E P V H G V
K3W I L W E P V H G V
E4D* I L K D P V H G V
E4C I L K C P V H G V
E4S I L K S P V H G V
E4T I L K T P V H G V
P5Y I L K E Y V H G V
V6Y I L K E P Y H G V
H7A I L K E P V A G V
G8E* I L K E P V H E V
G8F I L K E P V H F V
Abbreviations for the substitution peptides use the single-letter code
and conform to the following order: the wild-type (WT) amino acid,
the position at which the substitution occurs, and finally the substituted
amino acid. In the sequences, boldface type indicates the substitutions.
Previous studies have shown positions 2 and 9 to be anchor residues
(1).
*A natural variant of the pol epitope.
Chapel Hill/National Institute of Environmental Health Sci-
ences.
Generation of HIV-Specific CTL Lines. HIV pol-specific
CTL lines were generated from peripheral blood lymphocytes
(PBLs) of HIV-seropositive HLA-A2-positive individuals (do-
nors 25 and 32) as described previously (18, 19).
Cell Surface Stabilization Assay. The stabilization assay was
performed as described (20). Briefly, T2 cells were suspended
in AIM V serum-free medium (GIBCO) supplemented with
100 nM human 82-microglobulin and peptide (Sigma). The
peptide-pulsed cells were incubated overnight at 37°C. The
cells were stained for conformationally correct HLA-A*0201
with the monoclonal antibody BB7.2 (21), followed by fluo-
rescein isothiocyanate (FITC)-labeled goat anti-mouse IgG
antibody (Southern Biotechnology Associates). Cells were
analyzed by flow cytometry (FACScan, Becton Dickinson).
The mean channel for each peptide peak was determined on
a linear scale by using CYCLOPS software (Cytomation).
Assembly Assay. Peptide binding was analyzed with the T2
assembly assay essentially as described (15) except the heat
denaturation of the lysate prior to peptide addition was
eliminated. The HLA-A*0201 complexes were immunopre-
cipitated with BB7.2 (21). Immunoprecipitates were analyzed
by electrophoresis on a reducing SDS/12% polyacrylamide
gel. The gels were exposed overnight to a PhosphorImager
screen (Molecular Dynamics). The screen was analyzed and
quantitated by IMAGE QUANT 3.3 (Molecular Dynamics). The
volumes of the bands were quantitated, subtracting local
background. The resulting pixel value is directly proportional
to dpm and was plotted as described (15).
Complex Stability Assays. T2 cells were incubated with 100
,uM peptide and human /32-microglobulin as described for the
cell surface stabilization assay. After the overnight incubation,
the cells were incubated in RPMI medium 1640 containing
10% fetal calf serum and brefeldin A (Sigma) at 10 ,ug/ml to
block the egress of new class I molecules. After a 1-hr
incubation at 37°C in C02, the block of Golgi to cell surface
egress was maintained in medium containing brefeldinA at 0.5
,ug/ml. At the indicated time points, an aliquot was stained
with BB7.2 (21) as described above. All antibodies and wash
solutions contained brefeldin A at 0.5 ,ug/ml.
51Cr Release Assay. Recognition of the substituted peptides
by pol-specific CTLs was analyzed by a 51Cr release assay as
described (6). C1R-A2 or ClR-neo cells were used as targets.
The cells were incubated with peptide for 1 hr at 37°C.
pol-specific CTLs were added to each well at an effector-to-
target ratio of 4:1 unless otherwise noted. The graphs shown
for donor 25 were from a single set of experiments; however,
the data for donor 32 are representative of at least two assays.
For assays which measure CTL activity on vaccinia virus
(W)-infected targets, target cells were infected at a multi-
plicity of infection of 5 with W-pol, W-gag p17, or the
negative control, W-NP, which expresses the nucleoprotein
from influenza virus. After 1.5 hr of infection at 37°C, the cells
were washed twice, resuspended in medium, and incubated
overnight for expression of the VV construct genes. The
infected targets were labeled with 51Cr as described above.
In Vitro Immunization. Frozen PBLs from HIV-seroposi-
tive/HLA-A2-positive individuals (donors 4, 9, and 32) were
thawed and stimulated weekly with autologous Epstein-Barr
virus (EBV)-transformed B cells. These B cells were previ-
ously incubated with 10 ,uM peptide and irradiated [3000 rads
(30 Gy)] as described for the generation of CTL lines. Four
peptides were tested for production of pol-specific CTLs (WT
pol, HF, I1Y, and p17). Starting at day 14, the PBLs were
analyzed for their CTL reactivity in a standard 51Cr release
assay. Peptide-pulsed targets were autologous B cells pulsed
with wild-type pol or p17 peptides. For testing recognition of
endogenously processed antigen, cells of an HLA-A2+ B-cell
line AR (HLA-A1,2; B8, 44; Cw5) were infected with VV
constructs as described above.
Sequencing of HLA-A2 Subtypes. RNA was isolated from 4
x 106 cells, either EBV-transformed B cells or PBLs, using the
Micro FastTrack RNA isolation kit (Invitrogen). The HLA-A2
RNA was then amplified by using the GeneAmp RNA PCR kit
(Perkin-Elmer). The following antisense primer from exon 5
was used (5'-GCTCCAAAGAGAACCAGGCCAGCAATG-
3'), coupled with the sense primer from exon 1 (5'-
GCCGAGGATGGCCGTCATGGCGCCCCGAACC-3').
The amplification followed the supplier's instructions, except
that the MgCl2 concentration in the PCR reaction mixture was
increased to 5 mM. The 894-bp product was purified by Wizard
PCR Preps (Promega). DNA was sequenced at the University
of North Carolina at Chapel Hill Automated DNA Sequencing
Facility on a model 373A DNA Sequencer (Applied Biosys-
tems).
RESULTS
Affinity Analysis of pol Position 1 Substitutions. Eleven P1
amino acid substitutions of WT pol were analyzed for cell
surface stabilization of HLA-A*0201 (Table 1). This assay
measures the stabilization of empty cell surface heavy chains
or the exchange of peptide onto heavy chains (20). The Phe
(I1F) and Tyr (I1Y) substitution peptides were the only ones
able to stabilize cell surface HLA-A*0201 with an affinity
similar to that of the WT pol (Fig. 1A). The lower affinity of
the Trp substitution is representative of the remaining substi-
tutions. High peptide affinity has been posited to be important
for class I-restricted immune responses (22); therefore, the 11F
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FIG. 1. Binding of P1 substitu-
tion pol peptides. All binding ex-
periments used T2 cells (HLA-
A2, -B51) (16). (A) Cell surface
stabilization assay. Peptides are
represented as follows: 0, WT; El,
HF; A, I1Y; and v, 11W. Error bars
indicate SEM for three experi-
ments. (B and C) T2 assembly as-
says. WT pol is indicated as 0 in
both graphs. o denotes IlF in B
and IlY in C. Error bars indicate
SEM for three (B) or five (C)
assays.
and I1Y substitutions were analyzed further. The kinetics of
peptide binding to newly synthesized HLA-A*0201 was inves-
tigated in an in vitro assembly assay (15). In the assembly assay,
the peptide concentration of half-maximal assembly represents
the relative peptide affinity (15, 23). Both I1Y and IlF showed
an affinity similar to that of WT pol (Fig. 1 B and C).
The half-lives of the peptide/class I complexes at 37°C were
determined by complex stability assays. The stability of cell
surface HLA-A2 was significantly increased by both the I1Y
and I1F substitutions (Fig. 2). The half-life of the WT pol/
heavy chain complex is approximately 10 hr, whereas both the
I1F and I1Y substitutions increase the complex's half-life to
approximately 30 hr. Treating the cells with brefeldin A
showed that the number of conformationally correct HLA-A2
cannot be due to reloading of the peptide onto newly egressing
molecules. Since the antibody is conformationally sensitive to














Effect of P1 Substitutions on WT pol-Specific CTL Recog-
nition. Our mutational analysis of HLA-A*0201 showed dif-
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FIG. 2. Complex stability is increased with IlY and I1F. A cell
surface complex stability assay was conducted. After the peptide (0,
WT pol; El, I1Y; v, I1F; a, none) had been loaded overnight, the cells
were treated with brefeldinA to block the exit ofnew class I molecules.
After 1 hr, the cells were maintained in medium containing a lower,
less toxic, concentration of brefeldin A which maintained the egress
block. At the indicated time points, cells were stained for conforma-
tionally correct HLA-A2 by indirect immunofluorescence using
BB7.2. The mean channel fluorescence was determined for each peak.
The error bars indicated SEM for three experiments. If only a symbol
is apparent, the error is smaller than the symbol.
FIG. 3. CTL recognition of IlF and I1Y. Recognition of WT pol,
I1F, and I1Y by pol-specific CTL was analyzed by a standard 51Cr
release assay. Each peptide concentration was analyzed in duplicate.
(A and B) Recognition by donor 25 CTL line. (C and D) Recognition
by donor 32 CTL line. The negative control, C1R-neo (Neo) was
incubated with WT pol. Percent specific lysis of C1R-neo incubated
with substituted peptides was similar to that of Neo (data not shown).
In all panels WT pol recognition is denoted by *, and Neo is
represented as *. o indicates IlF (A and C) and I1Y (B and D).
Effector-to-target ratios (E/T) were as follows: 5 (A-C) and 3 (D). The
CTL lines from donor 25 (E) and 32 (F) were assayed on VV-infected
C1R-A2 or ClR-neo targets. All targets were infected at a multiplicity
of infection of 5. For E and F the negative control of C1R-neo targets
infected with VV-pol is noted as 0. C1R-A2 cells infected with no
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(6-9). CTL recognition of the substituted peptides was there-
fore analyzed with two independent WT pol-specific CTL
lines. I1F was recognized like WT pol by both CTL lines (Fig.
3 A and C). Donor 32 CTLs recognized I1Y (Fig. 3D), while
the CTL line from donor 25 showed reduced I1Y recognition
(Fig. 3B). These CTL lines are capable of recognizing endog-
enous antigen (Fig. 3 E and F). The difference in I1Y
recognition was not due to HLA-A2 subtype differences, since
both donors have the HLA-A*0201 subtype as determined by
DNA sequencing. The distinction in I1Y recognition suggests
a difference in T-cell repertoires.
In Vitro Immunogenicity of I1Y and I1F. The crucial ques-
tion for generating "improved" epitopes is whether the sub-
stitution peptide can stimulate T cells which recognize the WT
epitope. To address this question, PBLs were stimulated in
vitro to determine if the substituted peptide could elicit a WT
pol-specific CTL response. Since CTL generation from a naive
individual's PBLs is difficult, HLA-A2+ PBLs were used from
three HIV-1-seropositive donors: 4, 9, and 32. HIV-specific
CTLs can often be detected directly from seropositive PBLs
(12, 24); however, these donors exhibited minimal pol-specific
CTL reactivity after a single in vitro stimulation. pol-specific
CTL reactivity of WT pol peptide-pulsed, autologous EBV-
transformed B cells was less than 9% for all three donors.
Significant pol-specific CTL activity from these donors was not
detectable after 2 weeks of in vitro stimulation with WT pol,
suggesting low initial numbers of CTL precursors. Other
donors, like donor 25, exhibited high CTL activity (25%
specific lysis) after the initial week in culture. This high initial
CTL activity to theWT epitope provides a high background for
in vitro stimulation; thus, a believable increase over this high
response would be difficult to detect. The low responders were
specifically chosen to provide a large dynamic range for
detecting improved peptide stimulation. PBLs were stimulated
with each of the following peptides on autologous B cells: WT
pol, I1F, I1Y, and p17.
Starting at day 14, the stimulated PBLs from donor 32 were
analyzed for reactivity against autologous B cells pulsed with
either WT pol or p17 (Fig. 4A). The substituted peptides were
therefore tested for their ability to stimulate a WT pol-specific
CTL response. While significant pol-specific reactivity was not
seen in the WT pol-stimulated PBLs, IlY-stimulated PBLs
showed significantly higher WT pol-specific CTL reactivity at
day 14 (Fig. 4A). Significant pol-specific CTL reactivity was not

















stimulated PBLs from donor 32 showed p17-specific CTL
reactivity and no pol-specific reactivity (Fig. 4A). At 4 weeks,
a similar trend was apparent (data not shown).
Stimulation of PBLs from donors 4 and 9 with the I1Y
peptide also resulted in higher pol-specific CTL reactivity at
day 16 compared with PBLs stimulated with WT pol. For
donor 4, the pol-specific CTL reactivity ofWT pol-stimulated
PBLs and IlY-stimulated PBLs was 35% and 47%, respec-
tively, at an effector-to-target ratio of 30 (Fig. 4B). The
stimulated PBLs were also able to recognize the pol peptide
when it was produced endogenously by a VV construct ex-
pressing pol (Fig. 4C). In donor 9, WT pol-stimulated PBLs
and IlY-stimulated PBLs showed pol-specific reactivity of
12% and 23%, respectively, at an effector-to-target ratio of 30
(data not shown). Unlike donor 32, donor 4 was stimulated for
a WT pol-specific response by I1F. The difference in immu-
nogenicity of I1F between the two donors may be due to
HLA-A2 subtype or TCR repertoire differences. Thus, I1Y
stimulated a WT pol-specific response better than WT pol
from three donors' PBLs. These data suggest that I1Y is more
immunogenic than the WT pol peptide in vitro. Donor differ-
ences in the amount of CTL stimulation by I1F and I1Y clearly
demonstrate the role of T-cell repertoire on the availability of
reactive T cells.
Changes at Other Nonanchor Positions Lower Binding
and/or CTL Recognition. We tested 10 more substitutions at
positions 3 through 8 which were based on amino acids
frequently found at these positions in high-affinity HLA-
A*0201 peptides (Table 1) (4). The two natural variants of the
pol epitope, E4D and G8E, were also analyzed (11). All the
position 3 substitutions resulted in higher affinity peptides
which were not recognized by pol-specific CTLs (data not
shown). Almost all of the position 4-8 substitutions displayed
a similar phenotype: decreased binding in both assays and little
to no recognition by pol-specific CTLs (data not shown). P5Y
bound HLA-A*0201 like WT pol, and E4S was recognized by
one CTL line despite a lower binding affinity. Interestingly, the
natural variants bound HLA-A*0201 with an affinity similar to
that of WT pol; however, the recognition was reduced or
abolished (data not shown).
DISCUSSION
An epitope's affinity for an MHC molecule is believed to be
an important determinant for an immune response. In addition
C
pol 11Y 11F p17
FIG. 4. Recognition of WT pol
and p17 by in vitro stimulated
PBLs. PBL from donor 32 (A) or
donor 4 (B) were stimulated with
autologous EBV-transformed B
cells which were previously incu-
bated with WT pol, I1F, IlY, or
p17 (only A). At day 14, the cells
were tested for their recognition of
autologous B cells incubated with
WT pol (filled bars), p17 (open
bars), or no peptide (hatched bars),
in a standard 51Cr release assay (6).
Stimulated PBLs from donor 4
were also assayed for recognition
of VV-infected targets (C). AR
B-cell targets were infected as fol-
lows: no virus (hatched bars), VV
expressing p17 gag (open bars),
andVV expressing pol (filled bars).
The x-axis shows the peptide used
in stimulation. The effector-to-
- q target ratio was 50 (A), 30 (B), or
pol llY 12 (C).
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to peptide binding, CTL recognition of foreign antigen is
dependent on a productive interaction between the TCR and
MHC/peptide complexes. Given a productive (nonantagonist)
T-cell interaction, two models might describe the relationship
between peptide affinity and T-cell response. One model
suggests that a peptide's immunogenicity is proportional to its
affinity for MHC. Alternatively, immune responses occur once
a threshold peptide affinity or complex avidity is reached. In
this second model, increasing the peptide affinity beyond this
threshold would not enhance the specific immune response.
Understanding which model is more accurate will lead to
better developments in peptide therapeutics. The WT pol
epitope must possess a binding affinity above the T-cell
activation threshold, since many HLA-A2 HIV-positive indi-
viduals mount a response to this epitope (12). By improving the
pol epitope's affinity, the relationship between complex sta-
bility and immunogenicity can be examined.
Given the importance of nonanchor amino acids in peptide
affinity to MHC (3-5), improving the binding and recognition
of the HIV-1 pol peptide was investigated by altering the
nonanchor side chains. Since the majority of the P1 side chain
is buried within the class I cleft (14), P1 is an excellent position
to investigate increasing affinity without altering TCR inter-
action. Of the 11 P1 substitutions investigated, only 2 aromatic
substitutions, I1Y and I1F, bound cell surface HLA-A*0201 as
well as did WT pol (Fig. 1A). In the assembly assay, I1F and
I1Y showed similar affinities to WT pol (Fig. 1 B and C).
Both I1Y and I1F displayed an approximately 3-fold in-
crease in peptide-MHC complex half-lives at 37°C at the cell
surface. This prolongation of the half-life should increase the
peptide's cell surface concentration, thereby increasing the
avidity of the cell-cell interaction. An epitope present at high
cell surface concentration may be able to better stimulate
peptide-specific T cells. Recent studies in MHC class I models
have shown a correlation between peptide/MHC affinity and
the ability to detect a response (22).
Since the P1 side chain's orientation is similar among several
HLA-A*0201-restricted peptides (14), substitutions at P1
should not affect the overall peptide orientation. This idea is
supported by the CTL recognition of IlF and IlY (Fig. 3). CTL
lines from two different donors were able to recognize these
peptides. For the altered peptides to be effective as immuno-
gens, they must be recognized by the host as the WT epitope.
PBLs from HLA-A2, HIV-positive individuals were stimu-
lated in vitro with WT pol, I1Y, and I1F. The resulting PBLs
were analyzed for recognition of the WT pol peptide. I1Y was
able to stimulate WT pol-specific CTLs better than WT pol
from the PBLs of three seropositive donors (Fig. 4). These data
suggest that I1Y is more immunogenic than WT pol, presum-
ably due to the dramatic increase in the cell surface complex
stability. However, differences between donors in the amount
of CTL stimulation by I1F and I1Y clearly demonstrate the
important role of T-cell repertoire on the availability of
reactive T cells. In addition, the in vitro stimulated lymphocytes
were able to recognize the pol peptide when it was produced
endogenously by VV constructs (Fig. 4C). Thus, our stimula-
tion conditions did not preferentially stimulate T cells with
low-affinity receptors which recognize peptide-pulse, but not
endogenously processed, antigen.
The in vitro immunization analysis was conducted on PBLs
from seropositive donors. The question of previous T-cell
priming is evident. Unlike many donors (12, 24), the three
donors investigated all exhibited very low pol-specific reactiv-
ities even after 1 week of stimulation with WT pol peptide.
This suggested low initial numbers of CTL precursors in these
donors. It is unlikely that three independent donors were
previously primed in vivo with I1F or I1Y, since the HLA-A2-
restricted pol epitope is extremely conserved and neither the I1Y
nor the I1F substitution has been reported in HIV-1 strains (11).
Peptide immunization using I1Y maybe able to boost or maintain
pol-specific CTL activity in HIV-1-infected individuals. From
these experiments, it is unclear if IlY would stimulate CrLs in a
naive individual that could cross-react with WT pol. In the
HLA-A*0201/H-2 Kb transgenic mouse model, most high-
affmity peptides tested were also highly immunogenic (22).
We have identified a peptide, I1Y, which has (i) increased
complex stability for HLA-A*0201, (ii) maintains recognition
byWT pol-specific CTL lines, and (iii) is more stimulatory for
WT pol-specific CTLs in vitro. Thus, I1Y shows potential as a
vaccine component. Optimizing peptides through amino acid
substitution and immunogenicity analysis has significant ther-
apeutic ramifications for infectious disease, tumor immunol-
ogy, and autoimmunity.
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